Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Monitoring of Minimal Residual Disease (MRD) in Selected Patients With Colorectal Cancer (Stages II-IV) Using Analysis of Circulating Tumor DNA (ctDNA) by the ddPCR Method

NCT07895459 is registered in ClinicalTrials.gov with Masaryk Memorial Cancer Institute as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07895459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
Monitoring of Minimal Residual Disease (MRD) in Selected Patients With Colorectal Cancer (Stages II-IV) Using Analysis of Circulating Tumor DNA (ctDNA) by the ddPCR Method
Lead sponsor
Masaryk Memorial Cancer Institute
Phase
Not applicable
Overall status
Recruiting
Start date
February 7, 2023
Completion date
September 30, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer (diagnosis), colorectal neoplasms, minimal residual disease

Arms

As registered; 1 arm.

  • CRC Patient Cohort OtherBlood draw for ctDNA analysis

    Patients with colorectal cancer (stages II-IV) receiving standard care and undergoing routine blood draws for ctDNA/MRD monitoring.

Primary endpoints

Registered primary outcome measures; 1 primary.

  • ctDNA Detection Rate for Minimal Residual Disease Assessment Up to 24 months

    Percentage of patients with detectable circulating tumor DNA (ctDNA) in blood plasma (KRAS G12/G13 mutations assessed by ddPCR) to evaluate minimal residual disease (MRD) after primary therapy.

Lead sponsor's other trials

Masaryk Memorial Cancer Institute, most recent start first.

Similar trials

Same condition (Neoplasm, Residual) and phase, most recent start first.